Direkt zum Inhalt
Merck
  • Targeting Smad2 and Smad3 by miR-136 suppresses metastasis-associated traits of lung adenocarcinoma cells.

Targeting Smad2 and Smad3 by miR-136 suppresses metastasis-associated traits of lung adenocarcinoma cells.

Oncology research (2013-01-01)
Yi Yang, Lei Liu, Junchao Cai, Jueheng Wu, Hongyu Guan, Xun Zhu, Jie Yuan, Shengping Chen, Mengfeng Li
ZUSAMMENFASSUNG

TGF-β/Smad signaling induces epithelial-mesenchymal transition (EMT) and tumor metastasis. As essential mediators in this pathway, Smad2 and Smad3 have been extensively studied and found to promote EMT and the subsequent mobility as well as invasiveness of lung cancer cells. In the present study, we determined that miR-136 directly targeted Smad2 and Smad3, leading to reduced migration and invasiveness of lung adenocarcinoma (ADC) cell lines, accompanied by increased epithelial markers as well as decreased mesenchymal markers. Moreover, ectopic expression of either Smad2 or Smad3 partially restored the malignant phenotype of ADC cells overexpressing miR-136. Taken together, our data demonstrate that miR-136 may play a tumor-suppressive role by repressing EMT and prometastatic traits via targeting Smad2 and Smad3. The potent antimetastasis property of miR-136 and its multitarget mechanism provide new insights in developing novel therapeutic approaches.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-SMAD2 antibody produced in rabbit, IgG fraction of antiserum